Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

By B. Escudier, A. Płużańska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, Marek Filipek, B. Melichar, E. Bajetta and 5 more. The Lancet, 2007

2,273 citations recorded by the source corpus.

Subfields: Environmental Engineering, Geochemistry and Petrology, Mechanics of Materials

View Paper: https://www.semanticscholar.org/paper/79ccefe7ac24734304e785043a5323fa8733b73a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. Rini
2. T. Choueiri
3. Pedro C. Barata
4. B. Ljungberg
5. S. Halabi
6. C. Sternberg
7. J. Bellmunt
8. D. Heng

Citations in the corpus

• Treatment of renal cell carcinoma: Current status and future directions (2017, result): “5 to 11 months, and the median OS improved from 23 to 26 months, in favor of the experimental arms.(78,79,82) Both outcomes were shorter with temsirolimus compared with TKIs, which was investigated mainly in the poor-risk population with expected worse parameters.”
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Three vascular endothelial growth factor (VEGF)-targeted agents have demonstrated efficacy in pivotal phase III trials, mostly focused on good and intermediate patients: bevacizumab (combined with IFN), sunitinib and pazopanib [41-43].”
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “Three treatments have demonstrated efficacy in pivotal phase 3: bevacizumab [combined with interferon-alpha (IFN-α)], sunitinib and pazopanib [18–20].”
• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018, neutral): “United States 112 (26) 111 (26) 154 (28) 153 (28)”
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial (2010, result): “The effects of PFS and RR in the treatment-naive subpopulation observed in this phase III trial are comparable to published data for sunitinib and bevacizumab (with IFN).(8,10,11) When this study was initiated in April 2006, limited access to the multikinase inhibitors sunitinib and sorafenib preclu”
• Cabozantinib versus everolimus in advanced renal cell carcinoma (2015, neutral): “Diarrhea 245 (74) 38 (11) 88 (27) 7 (2)”
• EAU guidelines on renal cell carcinoma: 2014 update. (2010, neutral): “In a phase 3 trial, bevacizumab plus IFN-a was compared with IFN-a monotherapy [46].”
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. (2011, background): “Antiangiogenic therapies such as bevacizumab (BV), an antibody to vascular endothelial growth factor, have proven to be effective in improving outcomes in metastatic disease from several tumor types.(4-6) For MBC, combinations of BV and established chemotherapy regimens potentially offer new, more e”